FDA Pre-NDA Meeting (Schizophrenia)
TIMEFRAME: Q4 2025 (IMMINENT)
The Event: Reviva has a scheduled meeting with the FDA in Q4 2025 to discuss submitting a New Drug Application (NDA) for Brilaroxazine based solely on existing data (RECOVER-1 Phase 3 + OLE Long-term data).